Corpus
PascalFrancis
Racine
Corpus
Checkpoint
PascalFrancis
Racine
PascalFrancis
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance

Identifieur interne : 000039 ( PascalFrancis/Corpus ); précédent : 000038; suivant : 000040

Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance

Auteurs : A. Gabriella Wernicke ; Michael Shamis ; Kulbir K. Sidhu ; Bruce C. Turner ; Yevgenyia Goltser ; Imraan Khan ; Paul J. Christos ; Lydia T. Komarnicky-Kocher

Source :

RBID : Pascal:13-0097749

Descripteurs français

English descriptors

Abstract

Background: We assess complication rates in node negative breast cancer patients treated with breast radiotherapy (RT) only after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). Materials and Methods: Between 1995 and 2001, 226 women with AJCC stage I-II breast cancer were treated with lumpectomy, either SLND or SLND+ALND, and had available toxicities in follow-up: 111/136 (82%) and 115/129 (89%) in SLND and ALND groups, respectively. RT targeted the breast to median dose of 48.2 Gy (range, 46.0 to 50.4Gy) without axillary RT. Chi-square tests compared complication rates of 2 groups for axillary web syndrome (AWS), seroma, wound infection, decreased range of motion of the ipsilateral shoulder, paresthesia, and lymphedema. Results: Median follow-up was 9.9 years (range, 8.3-15.3 y). Median number of nodes assessed was 2 (range, 1-5) in SLND and 18 (range, 7-36) in ALND (P< 0.0001). Acute complications occurred during the first 2 years and were AWS, seroma, and wound infection. Incidences of seroma 5/111 (4.5%) in SLND and 16/115 (13.9%) in ALND (P < 0.02, respectively) and wound infection 3/111 (2.7%) in SLND and 10/115 (8.7%) in ALND (P < 0.05, respectively) differed significantly. AWS was not statistically different between the groups. At 10 years, the only chronic complications decreased were range of motion of the shoulder 46/111 (41.4%) in SLND and 92/115 (80.0%) in ALND (P< 0.0001), paresthesia 12/111 (10.8%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001), and lymphedema assessed by patients 10/111 (10.0%) in SLND and 39/115 (33.9%) in ALND (P<0.0001). Chronic lymphedema, assessed by clinicians, occurred in 6/111 (5.4%) in SLND and 21/115 (18.3%) in ALND cohorts, respectively (P < 0.0001). Conclusions: Our mature findings support that in patients with negative axillary nodal status SLND and breast RT provide excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

pA  
A01 01  1    @0 0277-3732
A02 01      @0 AJCODI
A03   1    @0 Am. j. clin. oncol.
A05       @2 36
A06       @2 1
A08 01  1  ENG  @1 Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance
A11 01  1    @1 GABRIELLA WERNICKE (A.)
A11 02  1    @1 SHAMIS (Michael)
A11 03  1    @1 SIDHU (Kulbir K.)
A11 04  1    @1 TURNER (Bruce C.)
A11 05  1    @1 GOLTSER (Yevgenyia)
A11 06  1    @1 KHAN (Imraan)
A11 07  1    @1 CHRISTOS (Paul J.)
A11 08  1    @1 KOMARNICKY-KOCHER (Lydia T.)
A14 01      @1 Department of Radiation Oncology, Weill Cornell Medical College of Cornell University @2 New York @3 USA @Z 1 aut.
A14 02      @1 Department of Public Health, Division of Biostatistics and Epidemiology, Weill Cornell Medical College of Cornell University @2 New York @3 USA @Z 7 aut.
A14 03      @1 Department of Biological Sciences, State University of New York @2 Stony Brook, NY @3 USA @Z 6 aut.
A14 04      @1 Department of Medical Sciences, Saint George University @2 Grenada, WI @3 USA @Z 2 aut.
A14 05      @1 Department of Radiation Oncology, Thomas Jefferson University Hospital @3 USA @Z 3 aut. @Z 4 aut.
A14 06      @1 Department of Radiation Oncology, Drexel University Hospital @2 Philadelphia, PA @3 USA @Z 8 aut.
A14 07      @1 Department of Biological Sciences, Brandeis University @2 Waltham, MA @3 USA @Z 5 aut.
A20       @1 12-19
A21       @1 2013
A23 01      @0 ENG
A43 01      @1 INIST @2 18032 @5 354000182534510030
A44       @0 0000 @1 © 2013 INIST-CNRS. All rights reserved.
A45       @0 47 ref.
A47 01  1    @0 13-0097749
A60       @1 P
A61       @0 A
A64 01  1    @0 American journal of clinical oncology
A66 01      @0 USA
C01 01    ENG  @0 Background: We assess complication rates in node negative breast cancer patients treated with breast radiotherapy (RT) only after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). Materials and Methods: Between 1995 and 2001, 226 women with AJCC stage I-II breast cancer were treated with lumpectomy, either SLND or SLND+ALND, and had available toxicities in follow-up: 111/136 (82%) and 115/129 (89%) in SLND and ALND groups, respectively. RT targeted the breast to median dose of 48.2 Gy (range, 46.0 to 50.4Gy) without axillary RT. Chi-square tests compared complication rates of 2 groups for axillary web syndrome (AWS), seroma, wound infection, decreased range of motion of the ipsilateral shoulder, paresthesia, and lymphedema. Results: Median follow-up was 9.9 years (range, 8.3-15.3 y). Median number of nodes assessed was 2 (range, 1-5) in SLND and 18 (range, 7-36) in ALND (P< 0.0001). Acute complications occurred during the first 2 years and were AWS, seroma, and wound infection. Incidences of seroma 5/111 (4.5%) in SLND and 16/115 (13.9%) in ALND (P < 0.02, respectively) and wound infection 3/111 (2.7%) in SLND and 10/115 (8.7%) in ALND (P < 0.05, respectively) differed significantly. AWS was not statistically different between the groups. At 10 years, the only chronic complications decreased were range of motion of the shoulder 46/111 (41.4%) in SLND and 92/115 (80.0%) in ALND (P< 0.0001), paresthesia 12/111 (10.8%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001), and lymphedema assessed by patients 10/111 (10.0%) in SLND and 39/115 (33.9%) in ALND (P<0.0001). Chronic lymphedema, assessed by clinicians, occurred in 6/111 (5.4%) in SLND and 21/115 (18.3%) in ALND cohorts, respectively (P < 0.0001). Conclusions: Our mature findings support that in patients with negative axillary nodal status SLND and breast RT provide excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.
C02 01  X    @0 002B26L
C02 02  X    @0 002B20E02
C03 01  X  FRE  @0 Complication @5 01
C03 01  X  ENG  @0 Complication @5 01
C03 01  X  SPA  @0 Complicación @5 01
C03 02  X  FRE  @0 Homme @5 02
C03 02  X  ENG  @0 Human @5 02
C03 02  X  SPA  @0 Hombre @5 02
C03 03  X  FRE  @0 Stade précoce @5 04
C03 03  X  ENG  @0 Early stage @5 04
C03 03  X  SPA  @0 Estadio precoz @5 04
C03 04  X  FRE  @0 Ganglion axillaire @5 05
C03 04  X  ENG  @0 Axillary ganglion @5 05
C03 04  X  SPA  @0 Ganglio axilar @5 05
C03 05  X  FRE  @0 Radiothérapie @5 08
C03 05  X  ENG  @0 Radiotherapy @5 08
C03 05  X  SPA  @0 Radioterapia @5 08
C03 06  X  FRE  @0 Traitement @5 09
C03 06  X  ENG  @0 Treatment @5 09
C03 06  X  SPA  @0 Tratamiento @5 09
C03 07  X  FRE  @0 Ganglion sentinelle @5 10
C03 07  X  ENG  @0 Sentinel lymph node @5 10
C03 07  X  SPA  @0 Ganglio centinela @5 10
C03 08  X  FRE  @0 Lymphadénectomie @5 11
C03 08  X  ENG  @0 Lymphadenectomy @5 11
C03 08  X  SPA  @0 Linfadenectomía @5 11
C03 09  X  FRE  @0 Cancer du sein @2 NM @5 14
C03 09  X  ENG  @0 Breast cancer @2 NM @5 14
C03 09  X  SPA  @0 Cáncer del pecho @2 NM @5 14
C03 10  X  FRE  @0 Lymphoedème @5 15
C03 10  X  ENG  @0 Lymphedema @5 15
C03 10  X  SPA  @0 Linfedema @5 15
C03 11  X  FRE  @0 Paresthésie @5 16
C03 11  X  ENG  @0 Paresthesia @5 16
C03 11  X  SPA  @0 Parestesia @5 16
C03 12  X  FRE  @0 Sérome @4 CD @5 96
C03 12  X  ENG  @0 Seroma @4 CD @5 96
C07 01  X  FRE  @0 Tumeur maligne @2 NM @5 39
C07 01  X  ENG  @0 Malignant tumor @2 NM @5 39
C07 01  X  SPA  @0 Tumor maligno @2 NM @5 39
C07 02  X  FRE  @0 Cancer @2 NM
C07 02  X  ENG  @0 Cancer @2 NM
C07 02  X  SPA  @0 Cáncer @2 NM
C07 03  X  FRE  @0 Pathologie de la glande mammaire @2 NM @5 40
C07 03  X  ENG  @0 Mammary gland diseases @2 NM @5 40
C07 03  X  SPA  @0 Glándula mamaria patología @2 NM @5 40
C07 04  X  FRE  @0 Pathologie du sein @2 NM @5 41
C07 04  X  ENG  @0 Breast disease @2 NM @5 41
C07 04  X  SPA  @0 Seno patología @2 NM @5 41
C07 05  X  FRE  @0 Pathologie de l'appareil circulatoire @5 42
C07 05  X  ENG  @0 Cardiovascular disease @5 42
C07 05  X  SPA  @0 Aparato circulatorio patología @5 42
C07 06  X  FRE  @0 Pathologie des vaisseaux lymphatiques @5 43
C07 06  X  ENG  @0 Lymphatic vessel disease @5 43
C07 06  X  SPA  @0 Linfático patología @5 43
C07 07  X  FRE  @0 Pathologie du système nerveux @5 44
C07 07  X  ENG  @0 Nervous system diseases @5 44
C07 07  X  SPA  @0 Sistema nervioso patología @5 44
C07 08  X  FRE  @0 Trouble neurologique @5 45
C07 08  X  ENG  @0 Neurological disorder @5 45
C07 08  X  SPA  @0 Trastorno neurológico @5 45
C07 09  X  FRE  @0 Trouble de la sensibilité @5 46
C07 09  X  ENG  @0 Sensitivity disorder @5 46
C07 09  X  SPA  @0 Trastorno sensibilidad @5 46
N21       @1 070

Format Inist (serveur)

NO : PASCAL 13-0097749 INIST
ET : Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance
AU : GABRIELLA WERNICKE (A.); SHAMIS (Michael); SIDHU (Kulbir K.); TURNER (Bruce C.); GOLTSER (Yevgenyia); KHAN (Imraan); CHRISTOS (Paul J.); KOMARNICKY-KOCHER (Lydia T.)
AF : Department of Radiation Oncology, Weill Cornell Medical College of Cornell University/New York/Etats-Unis (1 aut.); Department of Public Health, Division of Biostatistics and Epidemiology, Weill Cornell Medical College of Cornell University/New York/Etats-Unis (7 aut.); Department of Biological Sciences, State University of New York/Stony Brook, NY/Etats-Unis (6 aut.); Department of Medical Sciences, Saint George University/Grenada, WI/Etats-Unis (2 aut.); Department of Radiation Oncology, Thomas Jefferson University Hospital/Etats-Unis (3 aut., 4 aut.); Department of Radiation Oncology, Drexel University Hospital/Philadelphia, PA/Etats-Unis (8 aut.); Department of Biological Sciences, Brandeis University/Waltham, MA/Etats-Unis (5 aut.)
DT : Publication en série; Niveau analytique
SO : American journal of clinical oncology; ISSN 0277-3732; Coden AJCODI; Etats-Unis; Da. 2013; Vol. 36; No. 1; Pp. 12-19; Bibl. 47 ref.
LA : Anglais
EA : Background: We assess complication rates in node negative breast cancer patients treated with breast radiotherapy (RT) only after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). Materials and Methods: Between 1995 and 2001, 226 women with AJCC stage I-II breast cancer were treated with lumpectomy, either SLND or SLND+ALND, and had available toxicities in follow-up: 111/136 (82%) and 115/129 (89%) in SLND and ALND groups, respectively. RT targeted the breast to median dose of 48.2 Gy (range, 46.0 to 50.4Gy) without axillary RT. Chi-square tests compared complication rates of 2 groups for axillary web syndrome (AWS), seroma, wound infection, decreased range of motion of the ipsilateral shoulder, paresthesia, and lymphedema. Results: Median follow-up was 9.9 years (range, 8.3-15.3 y). Median number of nodes assessed was 2 (range, 1-5) in SLND and 18 (range, 7-36) in ALND (P< 0.0001). Acute complications occurred during the first 2 years and were AWS, seroma, and wound infection. Incidences of seroma 5/111 (4.5%) in SLND and 16/115 (13.9%) in ALND (P < 0.02, respectively) and wound infection 3/111 (2.7%) in SLND and 10/115 (8.7%) in ALND (P < 0.05, respectively) differed significantly. AWS was not statistically different between the groups. At 10 years, the only chronic complications decreased were range of motion of the shoulder 46/111 (41.4%) in SLND and 92/115 (80.0%) in ALND (P< 0.0001), paresthesia 12/111 (10.8%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001), and lymphedema assessed by patients 10/111 (10.0%) in SLND and 39/115 (33.9%) in ALND (P<0.0001). Chronic lymphedema, assessed by clinicians, occurred in 6/111 (5.4%) in SLND and 21/115 (18.3%) in ALND cohorts, respectively (P < 0.0001). Conclusions: Our mature findings support that in patients with negative axillary nodal status SLND and breast RT provide excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.
CC : 002B26L; 002B20E02
FD : Complication; Homme; Stade précoce; Ganglion axillaire; Radiothérapie; Traitement; Ganglion sentinelle; Lymphadénectomie; Cancer du sein; Lymphoedème; Paresthésie; Sérome
FG : Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Pathologie du système nerveux; Trouble neurologique; Trouble de la sensibilité
ED : Complication; Human; Early stage; Axillary ganglion; Radiotherapy; Treatment; Sentinel lymph node; Lymphadenectomy; Breast cancer; Lymphedema; Paresthesia; Seroma
EG : Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Cardiovascular disease; Lymphatic vessel disease; Nervous system diseases; Neurological disorder; Sensitivity disorder
SD : Complicación; Hombre; Estadio precoz; Ganglio axilar; Radioterapia; Tratamiento; Ganglio centinela; Linfadenectomía; Cáncer del pecho; Linfedema; Parestesia
LO : INIST-18032.354000182534510030
ID : 13-0097749

Links to Exploration step

Pascal:13-0097749

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance</title>
<author>
<name sortKey="Gabriella Wernicke, A" sort="Gabriella Wernicke, A" uniqKey="Gabriella Wernicke A" first="A." last="Gabriella Wernicke">A. Gabriella Wernicke</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Radiation Oncology, Weill Cornell Medical College of Cornell University</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Shamis, Michael" sort="Shamis, Michael" uniqKey="Shamis M" first="Michael" last="Shamis">Michael Shamis</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Department of Medical Sciences, Saint George University</s1>
<s2>Grenada, WI</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sidhu, Kulbir K" sort="Sidhu, Kulbir K" uniqKey="Sidhu K" first="Kulbir K." last="Sidhu">Kulbir K. Sidhu</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Department of Radiation Oncology, Thomas Jefferson University Hospital</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Turner, Bruce C" sort="Turner, Bruce C" uniqKey="Turner B" first="Bruce C." last="Turner">Bruce C. Turner</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Department of Radiation Oncology, Thomas Jefferson University Hospital</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Goltser, Yevgenyia" sort="Goltser, Yevgenyia" uniqKey="Goltser Y" first="Yevgenyia" last="Goltser">Yevgenyia Goltser</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Department of Biological Sciences, Brandeis University</s1>
<s2>Waltham, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Khan, Imraan" sort="Khan, Imraan" uniqKey="Khan I" first="Imraan" last="Khan">Imraan Khan</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Department of Biological Sciences, State University of New York</s1>
<s2>Stony Brook, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Christos, Paul J" sort="Christos, Paul J" uniqKey="Christos P" first="Paul J." last="Christos">Paul J. Christos</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Public Health, Division of Biostatistics and Epidemiology, Weill Cornell Medical College of Cornell University</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Komarnicky Kocher, Lydia T" sort="Komarnicky Kocher, Lydia T" uniqKey="Komarnicky Kocher L" first="Lydia T." last="Komarnicky-Kocher">Lydia T. Komarnicky-Kocher</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Department of Radiation Oncology, Drexel University Hospital</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">13-0097749</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0097749 INIST</idno>
<idno type="RBID">Pascal:13-0097749</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000039</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance</title>
<author>
<name sortKey="Gabriella Wernicke, A" sort="Gabriella Wernicke, A" uniqKey="Gabriella Wernicke A" first="A." last="Gabriella Wernicke">A. Gabriella Wernicke</name>
<affiliation>
<inist:fA14 i1="01">
<s1>Department of Radiation Oncology, Weill Cornell Medical College of Cornell University</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Shamis, Michael" sort="Shamis, Michael" uniqKey="Shamis M" first="Michael" last="Shamis">Michael Shamis</name>
<affiliation>
<inist:fA14 i1="04">
<s1>Department of Medical Sciences, Saint George University</s1>
<s2>Grenada, WI</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Sidhu, Kulbir K" sort="Sidhu, Kulbir K" uniqKey="Sidhu K" first="Kulbir K." last="Sidhu">Kulbir K. Sidhu</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Department of Radiation Oncology, Thomas Jefferson University Hospital</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Turner, Bruce C" sort="Turner, Bruce C" uniqKey="Turner B" first="Bruce C." last="Turner">Bruce C. Turner</name>
<affiliation>
<inist:fA14 i1="05">
<s1>Department of Radiation Oncology, Thomas Jefferson University Hospital</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Goltser, Yevgenyia" sort="Goltser, Yevgenyia" uniqKey="Goltser Y" first="Yevgenyia" last="Goltser">Yevgenyia Goltser</name>
<affiliation>
<inist:fA14 i1="07">
<s1>Department of Biological Sciences, Brandeis University</s1>
<s2>Waltham, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Khan, Imraan" sort="Khan, Imraan" uniqKey="Khan I" first="Imraan" last="Khan">Imraan Khan</name>
<affiliation>
<inist:fA14 i1="03">
<s1>Department of Biological Sciences, State University of New York</s1>
<s2>Stony Brook, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Christos, Paul J" sort="Christos, Paul J" uniqKey="Christos P" first="Paul J." last="Christos">Paul J. Christos</name>
<affiliation>
<inist:fA14 i1="02">
<s1>Department of Public Health, Division of Biostatistics and Epidemiology, Weill Cornell Medical College of Cornell University</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author>
<name sortKey="Komarnicky Kocher, Lydia T" sort="Komarnicky Kocher, Lydia T" uniqKey="Komarnicky Kocher L" first="Lydia T." last="Komarnicky-Kocher">Lydia T. Komarnicky-Kocher</name>
<affiliation>
<inist:fA14 i1="06">
<s1>Department of Radiation Oncology, Drexel University Hospital</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">American journal of clinical oncology</title>
<title level="j" type="abbreviated">Am. j. clin. oncol.</title>
<idno type="ISSN">0277-3732</idno>
<imprint>
<date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">American journal of clinical oncology</title>
<title level="j" type="abbreviated">Am. j. clin. oncol.</title>
<idno type="ISSN">0277-3732</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Axillary ganglion</term>
<term>Breast cancer</term>
<term>Complication</term>
<term>Early stage</term>
<term>Human</term>
<term>Lymphadenectomy</term>
<term>Lymphedema</term>
<term>Paresthesia</term>
<term>Radiotherapy</term>
<term>Sentinel lymph node</term>
<term>Seroma</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Complication</term>
<term>Homme</term>
<term>Stade précoce</term>
<term>Ganglion axillaire</term>
<term>Radiothérapie</term>
<term>Traitement</term>
<term>Ganglion sentinelle</term>
<term>Lymphadénectomie</term>
<term>Cancer du sein</term>
<term>Lymphoedème</term>
<term>Paresthésie</term>
<term>Sérome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Background: We assess complication rates in node negative breast cancer patients treated with breast radiotherapy (RT) only after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). Materials and Methods: Between 1995 and 2001, 226 women with AJCC stage I-II breast cancer were treated with lumpectomy, either SLND or SLND+ALND, and had available toxicities in follow-up: 111/136 (82%) and 115/129 (89%) in SLND and ALND groups, respectively. RT targeted the breast to median dose of 48.2 Gy (range, 46.0 to 50.4Gy) without axillary RT. Chi-square tests compared complication rates of 2 groups for axillary web syndrome (AWS), seroma, wound infection, decreased range of motion of the ipsilateral shoulder, paresthesia, and lymphedema. Results: Median follow-up was 9.9 years (range, 8.3-15.3 y). Median number of nodes assessed was 2 (range, 1-5) in SLND and 18 (range, 7-36) in ALND (P< 0.0001). Acute complications occurred during the first 2 years and were AWS, seroma, and wound infection. Incidences of seroma 5/111 (4.5%) in SLND and 16/115 (13.9%) in ALND (P < 0.02, respectively) and wound infection 3/111 (2.7%) in SLND and 10/115 (8.7%) in ALND (P < 0.05, respectively) differed significantly. AWS was not statistically different between the groups. At 10 years, the only chronic complications decreased were range of motion of the shoulder 46/111 (41.4%) in SLND and 92/115 (80.0%) in ALND (P< 0.0001), paresthesia 12/111 (10.8%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001), and lymphedema assessed by patients 10/111 (10.0%) in SLND and 39/115 (33.9%) in ALND (P<0.0001). Chronic lymphedema, assessed by clinicians, occurred in 6/111 (5.4%) in SLND and 21/115 (18.3%) in ALND cohorts, respectively (P < 0.0001). Conclusions: Our mature findings support that in patients with negative axillary nodal status SLND and breast RT provide excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0277-3732</s0>
</fA01>
<fA02 i1="01">
<s0>AJCODI</s0>
</fA02>
<fA03 i2="1">
<s0>Am. j. clin. oncol.</s0>
</fA03>
<fA05>
<s2>36</s2>
</fA05>
<fA06>
<s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>GABRIELLA WERNICKE (A.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>SHAMIS (Michael)</s1>
</fA11>
<fA11 i1="03" i2="1">
<s1>SIDHU (Kulbir K.)</s1>
</fA11>
<fA11 i1="04" i2="1">
<s1>TURNER (Bruce C.)</s1>
</fA11>
<fA11 i1="05" i2="1">
<s1>GOLTSER (Yevgenyia)</s1>
</fA11>
<fA11 i1="06" i2="1">
<s1>KHAN (Imraan)</s1>
</fA11>
<fA11 i1="07" i2="1">
<s1>CHRISTOS (Paul J.)</s1>
</fA11>
<fA11 i1="08" i2="1">
<s1>KOMARNICKY-KOCHER (Lydia T.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Radiation Oncology, Weill Cornell Medical College of Cornell University</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02">
<s1>Department of Public Health, Division of Biostatistics and Epidemiology, Weill Cornell Medical College of Cornell University</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03">
<s1>Department of Biological Sciences, State University of New York</s1>
<s2>Stony Brook, NY</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04">
<s1>Department of Medical Sciences, Saint George University</s1>
<s2>Grenada, WI</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05">
<s1>Department of Radiation Oncology, Thomas Jefferson University Hospital</s1>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06">
<s1>Department of Radiation Oncology, Drexel University Hospital</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="07">
<s1>Department of Biological Sciences, Brandeis University</s1>
<s2>Waltham, MA</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20>
<s1>12-19</s1>
</fA20>
<fA21>
<s1>2013</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>18032</s2>
<s5>354000182534510030</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>47 ref.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>13-0097749</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>American journal of clinical oncology</s0>
</fA64>
<fA66 i1="01">
<s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Background: We assess complication rates in node negative breast cancer patients treated with breast radiotherapy (RT) only after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). Materials and Methods: Between 1995 and 2001, 226 women with AJCC stage I-II breast cancer were treated with lumpectomy, either SLND or SLND+ALND, and had available toxicities in follow-up: 111/136 (82%) and 115/129 (89%) in SLND and ALND groups, respectively. RT targeted the breast to median dose of 48.2 Gy (range, 46.0 to 50.4Gy) without axillary RT. Chi-square tests compared complication rates of 2 groups for axillary web syndrome (AWS), seroma, wound infection, decreased range of motion of the ipsilateral shoulder, paresthesia, and lymphedema. Results: Median follow-up was 9.9 years (range, 8.3-15.3 y). Median number of nodes assessed was 2 (range, 1-5) in SLND and 18 (range, 7-36) in ALND (P< 0.0001). Acute complications occurred during the first 2 years and were AWS, seroma, and wound infection. Incidences of seroma 5/111 (4.5%) in SLND and 16/115 (13.9%) in ALND (P < 0.02, respectively) and wound infection 3/111 (2.7%) in SLND and 10/115 (8.7%) in ALND (P < 0.05, respectively) differed significantly. AWS was not statistically different between the groups. At 10 years, the only chronic complications decreased were range of motion of the shoulder 46/111 (41.4%) in SLND and 92/115 (80.0%) in ALND (P< 0.0001), paresthesia 12/111 (10.8%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001), and lymphedema assessed by patients 10/111 (10.0%) in SLND and 39/115 (33.9%) in ALND (P<0.0001). Chronic lymphedema, assessed by clinicians, occurred in 6/111 (5.4%) in SLND and 21/115 (18.3%) in ALND cohorts, respectively (P < 0.0001). Conclusions: Our mature findings support that in patients with negative axillary nodal status SLND and breast RT provide excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B26L</s0>
</fC02>
<fC02 i1="02" i2="X">
<s0>002B20E02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Complication</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Complication</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Complicación</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Homme</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Human</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Hombre</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Stade précoce</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Early stage</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Estadio precoz</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Ganglion axillaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Axillary ganglion</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Ganglio axilar</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Radiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Radiotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Radioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>Ganglion sentinelle</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG">
<s0>Sentinel lymph node</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA">
<s0>Ganglio centinela</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Lymphadénectomie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Lymphadenectomy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Linfadenectomía</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE">
<s0>Cancer du sein</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG">
<s0>Breast cancer</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA">
<s0>Cáncer del pecho</s0>
<s2>NM</s2>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE">
<s0>Lymphoedème</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG">
<s0>Lymphedema</s0>
<s5>15</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA">
<s0>Linfedema</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE">
<s0>Paresthésie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG">
<s0>Paresthesia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA">
<s0>Parestesia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE">
<s0>Sérome</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG">
<s0>Seroma</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Pathologie de la glande mammaire</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Pathologie du sein</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Breast disease</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Seno patología</s0>
<s2>NM</s2>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Pathologie de l'appareil circulatoire</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Cardiovascular disease</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Aparato circulatorio patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Pathologie des vaisseaux lymphatiques</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Lymphatic vessel disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Linfático patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Pathologie du système nerveux</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Nervous system diseases</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Sistema nervioso patología</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE">
<s0>Trouble neurologique</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG">
<s0>Neurological disorder</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA">
<s0>Trastorno neurológico</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE">
<s0>Trouble de la sensibilité</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG">
<s0>Sensitivity disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA">
<s0>Trastorno sensibilidad</s0>
<s5>46</s5>
</fC07>
<fN21>
<s1>070</s1>
</fN21>
</pA>
</standard>
<server>
<NO>PASCAL 13-0097749 INIST</NO>
<ET>Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance</ET>
<AU>GABRIELLA WERNICKE (A.); SHAMIS (Michael); SIDHU (Kulbir K.); TURNER (Bruce C.); GOLTSER (Yevgenyia); KHAN (Imraan); CHRISTOS (Paul J.); KOMARNICKY-KOCHER (Lydia T.)</AU>
<AF>Department of Radiation Oncology, Weill Cornell Medical College of Cornell University/New York/Etats-Unis (1 aut.); Department of Public Health, Division of Biostatistics and Epidemiology, Weill Cornell Medical College of Cornell University/New York/Etats-Unis (7 aut.); Department of Biological Sciences, State University of New York/Stony Brook, NY/Etats-Unis (6 aut.); Department of Medical Sciences, Saint George University/Grenada, WI/Etats-Unis (2 aut.); Department of Radiation Oncology, Thomas Jefferson University Hospital/Etats-Unis (3 aut., 4 aut.); Department of Radiation Oncology, Drexel University Hospital/Philadelphia, PA/Etats-Unis (8 aut.); Department of Biological Sciences, Brandeis University/Waltham, MA/Etats-Unis (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>American journal of clinical oncology; ISSN 0277-3732; Coden AJCODI; Etats-Unis; Da. 2013; Vol. 36; No. 1; Pp. 12-19; Bibl. 47 ref.</SO>
<LA>Anglais</LA>
<EA>Background: We assess complication rates in node negative breast cancer patients treated with breast radiotherapy (RT) only after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). Materials and Methods: Between 1995 and 2001, 226 women with AJCC stage I-II breast cancer were treated with lumpectomy, either SLND or SLND+ALND, and had available toxicities in follow-up: 111/136 (82%) and 115/129 (89%) in SLND and ALND groups, respectively. RT targeted the breast to median dose of 48.2 Gy (range, 46.0 to 50.4Gy) without axillary RT. Chi-square tests compared complication rates of 2 groups for axillary web syndrome (AWS), seroma, wound infection, decreased range of motion of the ipsilateral shoulder, paresthesia, and lymphedema. Results: Median follow-up was 9.9 years (range, 8.3-15.3 y). Median number of nodes assessed was 2 (range, 1-5) in SLND and 18 (range, 7-36) in ALND (P< 0.0001). Acute complications occurred during the first 2 years and were AWS, seroma, and wound infection. Incidences of seroma 5/111 (4.5%) in SLND and 16/115 (13.9%) in ALND (P < 0.02, respectively) and wound infection 3/111 (2.7%) in SLND and 10/115 (8.7%) in ALND (P < 0.05, respectively) differed significantly. AWS was not statistically different between the groups. At 10 years, the only chronic complications decreased were range of motion of the shoulder 46/111 (41.4%) in SLND and 92/115 (80.0%) in ALND (P< 0.0001), paresthesia 12/111 (10.8%) in SLND and 39/115 (33.9%) in ALND (P < 0.0001), and lymphedema assessed by patients 10/111 (10.0%) in SLND and 39/115 (33.9%) in ALND (P<0.0001). Chronic lymphedema, assessed by clinicians, occurred in 6/111 (5.4%) in SLND and 21/115 (18.3%) in ALND cohorts, respectively (P < 0.0001). Conclusions: Our mature findings support that in patients with negative axillary nodal status SLND and breast RT provide excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.</EA>
<CC>002B26L; 002B20E02</CC>
<FD>Complication; Homme; Stade précoce; Ganglion axillaire; Radiothérapie; Traitement; Ganglion sentinelle; Lymphadénectomie; Cancer du sein; Lymphoedème; Paresthésie; Sérome</FD>
<FG>Tumeur maligne; Cancer; Pathologie de la glande mammaire; Pathologie du sein; Pathologie de l'appareil circulatoire; Pathologie des vaisseaux lymphatiques; Pathologie du système nerveux; Trouble neurologique; Trouble de la sensibilité</FG>
<ED>Complication; Human; Early stage; Axillary ganglion; Radiotherapy; Treatment; Sentinel lymph node; Lymphadenectomy; Breast cancer; Lymphedema; Paresthesia; Seroma</ED>
<EG>Malignant tumor; Cancer; Mammary gland diseases; Breast disease; Cardiovascular disease; Lymphatic vessel disease; Nervous system diseases; Neurological disorder; Sensitivity disorder</EG>
<SD>Complicación; Hombre; Estadio precoz; Ganglio axilar; Radioterapia; Tratamiento; Ganglio centinela; Linfadenectomía; Cáncer del pecho; Linfedema; Parestesia</SD>
<LO>INIST-18032.354000182534510030</LO>
<ID>13-0097749</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000039 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000039 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:13-0097749
   |texte=   Complication Rates in Patients With Negative Axillary Nodes 10 Years After Local Breast Radiotherapy After Either Sentinel Lymph Node Dissection or Axillary Clearance
}}
Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024